CyDex Licenses Captisol(R) to Proteolix, Inc. for Promising Oncology Compound

CyDex Licenses Captisol(R) to Proteolix, Inc. for Promising Oncology Compound: "LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced an agreement licensing its Captisol� enabling technology to Proteolix, Inc. for use with a proteasome inhibitor that has shown promise in treating certain cancers such as multiple myeloma and mantle cell lymphoma."